<DOC>
	<DOCNO>NCT01439919</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy SSR411298 200 mg daily compare placebo adjunctive treatment persistent cancer pain base Numeric Rating Scale ( NRS ) . Secondary Objectives : - To evaluate effect SSR411298 200 mg daily pain , breakthrough pain frequency , background therapy utilization , mood , patient satisfaction pain relief , nausea , constipation , healthcare utilization quality life ; - To evaluate tolerability safety SSR411298 adjunctive treatment persistent cancer pain ; - To characterize patient disease , term cancer , cancer treatment , cancer pain cancer pain treatment ; - To evaluate pharmacokinetic ( PK ) exposure SSR411298 adjunctive treatment persistent cancer pain ; - To assess endocannabinoid plasma concentration .</brief_summary>
	<brief_title>A Clinical Trial Assess Clinical Benefit SSR411298 Adjunctive Treatment Persistent Cancer Pain</brief_title>
	<detailed_description>The total study duration participant 6 week ( 1-week screening , 4-week treatment 1-week post-treatment follow-up ) . Participants continue receive WHO Step 2 3 cancer pain treatment background therapy .</detailed_description>
	<criteria>Inclusion criterion : Patient moderate severe , persistent cancer pain receive World Health Organization ( WHO ) Step 2 3 cancer pain treatment : Pain generator ( source pain ) must primarily due underlie cancer cancer treatment ; Pain generator ( source pain ) must classify either primarily nociceptive primarily neuropathic ; Pain severity must moderate severe average NRS score â‰¥4 screen week . Exclusion criterion : Instability pain screen week ; Use prohibit adjuvant pain treatment week prior study entry plan use medication study ; Current use medication contain tetrahydrocannabinol ( THC ) ; Chemotherapy within 4 week study entry chemotherapy plan study ( stable regiment hormonal therapy permit ) ; Radiotherapy within 4 week study entry radiotherapy plan study ( hemostatic palliative radiotherapy permit ) ; Cancer relate surgery within 4 week study entry cancerrelated surgery plan study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>